Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer
| Autor: | Chin-Lee Wu, Zhi duan Cai, Yang jia Zhuo, Yue ping Wan, Sheng da Song, Song Wan, Ze zhen Liu, Wei-de Zhong, Jian jiang Xie, Wei Hua, Zhou da Cai |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine Biochemical recurrence Apoptosis Protein Serine-Threonine Kinases Metastasis 03 medical and health sciences Prostate cancer Cell Movement Cell Line Tumor Humans Medicine Neoplasm Invasiveness Neoplasm Metastasis Aged Cell Proliferation Pharmacology Tissue microarray business.industry Cell growth Cell Cycle Prostatic Neoplasms General Medicine Middle Aged Cell cycle Prognosis medicine.disease Xenograft Model Antitumor Assays 030104 developmental biology Tissue Array Analysis Tumor progression Disease Progression Cancer research Immunohistochemistry business |
| Zdroj: | Biomedicine & Pharmacotherapy. 102:531-538 |
| ISSN: | 0753-3322 |
| Popis: | Serine/Arginine-Rich Protein-Specific Kinase-2 (SRSF protein kinase-2, SRPK2) is up-regulated in multiple human tumors. However, the expression, function and clinical significance of SRPK2 in prostate cancer (PCa) has not yet been understood. We therefore aimed to determine the association of SRPK2 with tumor progression and metastasis in PCa patients in our present study. The expression of SRPK2 was detected by some public datasets and validated using a clinical tissue microarray (TMA) by immunohistochemistry. The association of SRPK2 expression with various clinicopathological characteristics of PCa patients was subsequently statistically analyzed based on the The Cancer Genome Atlas (TCGA) dataset and clinical TMA. The effects of SRPK2 on cancer cell proliferation, migration, invasion, cell cycle progression, apoptosis and tumor growth were then respectively investigated using in vitro and in vivo experiments. First, public datasets showed that SRPK2 expression was greater in PCa tissues when compared with non-cancerous tissues. Statistical analysis demonstrated that high expression of SRPK2 was significantly correlated with a higher Gleason Score, advanced pathological stage and the presence of tumor metastasis in the TCGA Dataset (all P < 0.01). Similar correlations between SRPK2 and a higher Gleason Score or advanced pathological stage were also identified in the TMA (P < 0.05). Kaplan-Meier curve analyses showed that the biochemical recurrence (BCR)-free time of PCa patients with SRPK2 high expression was shorter than for those with SRPK2 low expression (P < 0.05). Second, cell function experiments in PCa cell lines revealed that enhanced SRPK2 expression could promote cell proliferation, migration, invasion and cell cycle progression but suppress tumor cell apoptosis in vitro. Xenograft experiments showed that SRPK2 promoted tumor growth in vivo. In conclusion, our data demonstrated that SRPK2 may play an important role in the progression and metastasis of PCa, which suggests that it might be a potential therapeutic target for PCa clinical therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect